Acadia Pharmaceuticals cuts 2026 R&D guidance and shares fall about 22%
FROM THE WIRE · FINANCE.YAHOO.COM
Acadia Pharmaceuticals (ACAD) just paired fresh quarterly results with a guidance tweak and new Alzheimer's trial data, giving investors several moving parts to assess at the same time. The reaction has been harsh. Acadia Pharmaceuticals' share price has fallen about 22% over…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishThe R&D guidance cut and new Alzheimer's data drove a sharp drop in the shares.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The shares fell about 22% over the last day.
- 02The decline is roughly 44% over 90 days.
- 03The stock revised 2026 R&D guidance alongside new Alzheimer's trial data.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets